Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 373 entries
Sorted by: Best Match Show Resources per page
Azithromycin and COPD Exacerbations in the Presence or Absence of Symptoms or Active Treatment for Gastroesophageal Reflux.

Chronic obstructive pulmonary diseases (Miami, Fla.)

Ramos FL, Lindberg SM, Krahnke JS, Connett J, Albert RK, Criner GJ.
PMID: 29114567
Chronic Obstr Pulm Dis. 2014 Sep 25;1(2):221-228. doi: 10.15326/jcopdf.1.2.2014.0132.

No abstract available.

Cite
Ramos FL, Lindberg SM, Krahnke JS, et al. Azithromycin and COPD Exacerbations in the Presence or Absence of Symptoms or Active Treatment for Gastroesophageal Reflux. Chronic Obstr Pulm Dis. 2014;1(2):221-228doi: 10.15326/jcopdf.1.2.2014.0132.
Ramos, F. L., Lindberg, S. M., Krahnke, J. S., Connett, J., Albert, R. K., Criner, G. J. (2014). Azithromycin and COPD Exacerbations in the Presence or Absence of Symptoms or Active Treatment for Gastroesophageal Reflux. Chronic obstructive pulmonary diseases (Miami, Fla.), 1(2), 221-228. https://doi.org/10.15326/jcopdf.1.2.2014.0132
Ramos, Frederick L, et al. "Azithromycin and COPD Exacerbations in the Presence or Absence of Symptoms or Active Treatment for Gastroesophageal Reflux." Chronic obstructive pulmonary diseases (Miami, Fla.) vol. 1,2 (2014): 221-228. doi: https://doi.org/10.15326/jcopdf.1.2.2014.0132
Ramos FL, Lindberg SM, Krahnke JS, Connett J, Albert RK, Criner GJ. Azithromycin and COPD Exacerbations in the Presence or Absence of Symptoms or Active Treatment for Gastroesophageal Reflux. Chronic Obstr Pulm Dis. 2014 Sep 25;1(2):221-228. doi: 10.15326/jcopdf.1.2.2014.0132. PMID: 29114567; PMCID: PMC5593427.
Copy Download .nbib Format: NLM
Morphologic Response of the Pulmonary Vasculature to Endoscopic Lung Volume Reduction.

Chronic obstructive pulmonary diseases (Miami, Fla.)

Rahaghi FN, Come CE, Ross J, Harmouche R, Diaz AA, Estepar RS, Washko G.
PMID: 26587564
Chronic Obstr Pulm Dis. 2015;2(3):214-222. doi: 10.15326/jcopdf.2.3.2014.0164.

INTRODUCTION: Endoscopic Lung Volume Reduction has been used to reduce lung hyperinflation in selected patients with severe emphysema. Little is known about the effect of this procedure on the intraparenchymal pulmonary vasculature. In this study we used CT based...

Cite
Rahaghi FN, Come CE, Ross J, et al. Morphologic Response of the Pulmonary Vasculature to Endoscopic Lung Volume Reduction. Chronic Obstr Pulm Dis. 2015;2(3):214-222doi: 10.15326/jcopdf.2.3.2014.0164.
Rahaghi, F. N., Come, C. E., Ross, J., Harmouche, R., Diaz, A. A., Estepar, R. S., & Washko, G. (2015). Morphologic Response of the Pulmonary Vasculature to Endoscopic Lung Volume Reduction. Chronic obstructive pulmonary diseases (Miami, Fla.), 2(3), 214-222. https://doi.org/10.15326/jcopdf.2.3.2014.0164
Rahaghi, Farbod N, et al. "Morphologic Response of the Pulmonary Vasculature to Endoscopic Lung Volume Reduction." Chronic obstructive pulmonary diseases (Miami, Fla.) vol. 2,3 (2015): 214-222. doi: https://doi.org/10.15326/jcopdf.2.3.2014.0164
Rahaghi FN, Come CE, Ross J, Harmouche R, Diaz AA, Estepar RS, Washko G. Morphologic Response of the Pulmonary Vasculature to Endoscopic Lung Volume Reduction. Chronic Obstr Pulm Dis. 2015;2(3):214-222. doi: 10.15326/jcopdf.2.3.2014.0164. PMID: 26587564; PMCID: PMC4648543.
Copy Download .nbib Format: NLM
PHYSIOLOGIC AND QUANTITATIVE COMPUTED TOMOGRAPHY DIFFERENCES BETWEEN CENTRILOBULAR AND PANLOBULAR EMPHYSEMA IN COPD.

Chronic obstructive pulmonary diseases (Miami, Fla.)

Sverzellati N, Lynch DA, Pistolesi M, Kauczor HU, Grenier PA, Wilson C, Crapo JD.
PMID: 26029738
Chronic Obstr Pulm Dis. 2014;1(1):125-132. doi: 10.15326/jcopdf.1.1.2014.0114.

BACKGROUND: The purpose was to define the differences between centrilobular (CLE) and panlobular emphysema (PLE) phenotypes in cigarette smokers with COPD by a combined qualitative-quantitative computed tomography (CT) analysis.METHODS: Chest CT scans of 116 cigarette smokers were visually scored...

Cite
Sverzellati N, Lynch DA, Pistolesi M, et al. PHYSIOLOGIC AND QUANTITATIVE COMPUTED TOMOGRAPHY DIFFERENCES BETWEEN CENTRILOBULAR AND PANLOBULAR EMPHYSEMA IN COPD. Chronic Obstr Pulm Dis. 2014;1(1):125-132doi: 10.15326/jcopdf.1.1.2014.0114.
Sverzellati, N., Lynch, D. A., Pistolesi, M., Kauczor, H. U., Grenier, P. A., Wilson, C., & Crapo, J. D. (2014). PHYSIOLOGIC AND QUANTITATIVE COMPUTED TOMOGRAPHY DIFFERENCES BETWEEN CENTRILOBULAR AND PANLOBULAR EMPHYSEMA IN COPD. Chronic obstructive pulmonary diseases (Miami, Fla.), 1(1), 125-132. https://doi.org/10.15326/jcopdf.1.1.2014.0114
Sverzellati, Nicola, et al. "PHYSIOLOGIC AND QUANTITATIVE COMPUTED TOMOGRAPHY DIFFERENCES BETWEEN CENTRILOBULAR AND PANLOBULAR EMPHYSEMA IN COPD." Chronic obstructive pulmonary diseases (Miami, Fla.) vol. 1,1 (2014): 125-132. doi: https://doi.org/10.15326/jcopdf.1.1.2014.0114
Sverzellati N, Lynch DA, Pistolesi M, Kauczor HU, Grenier PA, Wilson C, Crapo JD. PHYSIOLOGIC AND QUANTITATIVE COMPUTED TOMOGRAPHY DIFFERENCES BETWEEN CENTRILOBULAR AND PANLOBULAR EMPHYSEMA IN COPD. Chronic Obstr Pulm Dis. 2014;1(1):125-132. doi: 10.15326/jcopdf.1.1.2014.0114. PMID: 26029738; PMCID: PMC4447143.
Copy Download .nbib Format: NLM
Can Commercially Available Pedometers Be Used For Physical Activity Monitoring In Patients With COPD Following Exacerbations?.

Chronic obstructive pulmonary diseases (Miami, Fla.)

Prieto-Centurion V, Bracken N, Norwick L, Zaidi F, Mutso AA, Morken V, Coultas DB, Rand CS, Marquez DX, Krishnan JA.
PMID: 27547817
Chronic Obstr Pulm Dis. 2016;3(3):636-642. doi: 10.15326/jcopdf.3.3.2015.0164.

BACKGROUND: Commercially available pedometers have been used as tools to measure endpoints in studies evaluating physical activity promotion programs. However, their accuracy in patients recovering from COPD exacerbations is unknown. The objectives of this study were to 1) assess...

Cite
Prieto-Centurion V, Bracken N, Norwick L, et al. Can Commercially Available Pedometers Be Used For Physical Activity Monitoring In Patients With COPD Following Exacerbations?. Chronic Obstr Pulm Dis. 2016;3(3):636-642doi: 10.15326/jcopdf.3.3.2015.0164.
Prieto-Centurion, V., Bracken, N., Norwick, L., Zaidi, F., Mutso, A. A., Morken, V., Coultas, D. B., Rand, C. S., Marquez, D. X., & Krishnan, J. A. (2016). Can Commercially Available Pedometers Be Used For Physical Activity Monitoring In Patients With COPD Following Exacerbations?. Chronic obstructive pulmonary diseases (Miami, Fla.), 3(3), 636-642. https://doi.org/10.15326/jcopdf.3.3.2015.0164
Prieto-Centurion, Valentin, et al. "Can Commercially Available Pedometers Be Used For Physical Activity Monitoring In Patients With COPD Following Exacerbations?." Chronic obstructive pulmonary diseases (Miami, Fla.) vol. 3,3 (2016): 636-642. doi: https://doi.org/10.15326/jcopdf.3.3.2015.0164
Prieto-Centurion V, Bracken N, Norwick L, Zaidi F, Mutso AA, Morken V, Coultas DB, Rand CS, Marquez DX, Krishnan JA. Can Commercially Available Pedometers Be Used For Physical Activity Monitoring In Patients With COPD Following Exacerbations?. Chronic Obstr Pulm Dis. 2016;3(3):636-642. doi: 10.15326/jcopdf.3.3.2015.0164. PMID: 27547817; PMCID: PMC4989920.
Copy Download .nbib Format: NLM
Re-Defining Lower Limit of Normal for FEV.

Chronic obstructive pulmonary diseases (Miami, Fla.)

Hansen JE, Porszasz J, Casaburi R, Stringer WW.
PMID: 28848835
Chronic Obstr Pulm Dis. 2015 Mar 10;2(2):94-102. doi: 10.15326/jcopdf.2.2.2014.0144.

No abstract available.

Cite
Hansen JE, Porszasz J, Casaburi R, et al. Re-Defining Lower Limit of Normal for FEV. Chronic Obstr Pulm Dis. 2015;2(2):94-102doi: 10.15326/jcopdf.2.2.2014.0144.
Hansen, J. E., Porszasz, J., Casaburi, R., & Stringer, W. W. (2015). Re-Defining Lower Limit of Normal for FEV. Chronic obstructive pulmonary diseases (Miami, Fla.), 2(2), 94-102. https://doi.org/10.15326/jcopdf.2.2.2014.0144
Hansen, James E, et al. "Re-Defining Lower Limit of Normal for FEV." Chronic obstructive pulmonary diseases (Miami, Fla.) vol. 2,2 (2015): 94-102. doi: https://doi.org/10.15326/jcopdf.2.2.2014.0144
Hansen JE, Porszasz J, Casaburi R, Stringer WW. Re-Defining Lower Limit of Normal for FEV. Chronic Obstr Pulm Dis. 2015 Mar 10;2(2):94-102. doi: 10.15326/jcopdf.2.2.2014.0144. PMID: 28848835; PMCID: PMC5556964.
Copy Download .nbib Format: NLM
Effects of GOLD-Adherent Prescribing on COPD Symptom Burden, Exacerbations, and Health Care Utilization in a Real-World Setting.

Chronic obstructive pulmonary diseases (Miami, Fla.)

Mannino DM, Yu TC, Zhou H, Higuchi K.
PMID: 28848845
Chronic Obstr Pulm Dis. 2015 Jun 19;2(3):223-235. doi: 10.15326/jcopdf.2.3.2014.0151.

Global initiative for chronic Obstructive Lung Disease (GOLD) guidelines recommend specific drug therapy protocols for chronic obstructive pulmonary disease (COPD) patients based on symptoms and exacerbation risk. This study used electronic health records (EHRs) to assess the effect of...

Cite
Mannino DM, Yu TC, Zhou H, et al. Effects of GOLD-Adherent Prescribing on COPD Symptom Burden, Exacerbations, and Health Care Utilization in a Real-World Setting. Chronic Obstr Pulm Dis. 2015;2(3):223-235doi: 10.15326/jcopdf.2.3.2014.0151.
Mannino, D. M., Yu, T. C., Zhou, H., & Higuchi, K. (2015). Effects of GOLD-Adherent Prescribing on COPD Symptom Burden, Exacerbations, and Health Care Utilization in a Real-World Setting. Chronic obstructive pulmonary diseases (Miami, Fla.), 2(3), 223-235. https://doi.org/10.15326/jcopdf.2.3.2014.0151
Mannino, David M, et al. "Effects of GOLD-Adherent Prescribing on COPD Symptom Burden, Exacerbations, and Health Care Utilization in a Real-World Setting." Chronic obstructive pulmonary diseases (Miami, Fla.) vol. 2,3 (2015): 223-235. doi: https://doi.org/10.15326/jcopdf.2.3.2014.0151
Mannino DM, Yu TC, Zhou H, Higuchi K. Effects of GOLD-Adherent Prescribing on COPD Symptom Burden, Exacerbations, and Health Care Utilization in a Real-World Setting. Chronic Obstr Pulm Dis. 2015 Jun 19;2(3):223-235. doi: 10.15326/jcopdf.2.3.2014.0151. PMID: 28848845; PMCID: PMC5556885.
Copy Download .nbib Format: NLM
CD4+ T-Cell Profiles and Peripheral Blood Ex-Vivo Responses to T-Cell Directed Stimulation Delineate COPD Phenotypes.

Chronic obstructive pulmonary diseases (Miami, Fla.)

Roberts MEP, Higgs BW, Brohawn P, Pilataxi F, Guo X, Kuziora M, Bowler RP, White WI.
PMID: 28848849
Chronic Obstr Pulm Dis. 2015 Aug 23;2(4):268-280. doi: 10.15326/jcopdf.2.4.2015.0131.

The heterogeneous clinical phenotypes of chronic obstructive pulmonary disease (COPD) challenge successful drug development. To identify COPD subgroups beyond clinical phenotypes, we interrogated blood immune cell profiles and ex-vivo responses of current and former smokers, with or without COPD,...

Cite
Roberts MEP, Higgs BW, Brohawn P, et al. CD4+ T-Cell Profiles and Peripheral Blood Ex-Vivo Responses to T-Cell Directed Stimulation Delineate COPD Phenotypes. Chronic Obstr Pulm Dis. 2015;2(4):268-280doi: 10.15326/jcopdf.2.4.2015.0131.
Roberts, M. E. P., Higgs, B. W., Brohawn, P., Pilataxi, F., Guo, X., Kuziora, M., Bowler, R. P., & White, W. I. (2015). CD4+ T-Cell Profiles and Peripheral Blood Ex-Vivo Responses to T-Cell Directed Stimulation Delineate COPD Phenotypes. Chronic obstructive pulmonary diseases (Miami, Fla.), 2(4), 268-280. https://doi.org/10.15326/jcopdf.2.4.2015.0131
Roberts, Mustimbo E P, et al. "CD4+ T-Cell Profiles and Peripheral Blood Ex-Vivo Responses to T-Cell Directed Stimulation Delineate COPD Phenotypes." Chronic obstructive pulmonary diseases (Miami, Fla.) vol. 2,4 (2015): 268-280. doi: https://doi.org/10.15326/jcopdf.2.4.2015.0131
Roberts MEP, Higgs BW, Brohawn P, Pilataxi F, Guo X, Kuziora M, Bowler RP, White WI. CD4+ T-Cell Profiles and Peripheral Blood Ex-Vivo Responses to T-Cell Directed Stimulation Delineate COPD Phenotypes. Chronic Obstr Pulm Dis. 2015 Aug 23;2(4):268-280. doi: 10.15326/jcopdf.2.4.2015.0131. PMID: 28848849; PMCID: PMC5556823.
Copy Download .nbib Format: NLM
Validation of the St. George's Respiratory Questionnaire in Nepal.

Chronic obstructive pulmonary diseases (Miami, Fla.)

Sherpa CT, LeClerq SL, Singh S, Naithani N, Pangeni R, Karki A, Chokhani RK, Han M, Gyetko M, Tielsch JM, Checkley W.
PMID: 28848850
Chronic Obstr Pulm Dis. 2015 Sep 02;2(4):281-289. doi: 10.15326/jcopdf.2.4.2014.0156.

The St. George's Respiratory Questionnaire (SGRQ) is a standardized questionnaire for measuring impaired health and perceived well-being in chronic airway disease, but it is not available in the Nepali language. We translated the original SGRQ into Nepali and validated...

Cite
Sherpa CT, LeClerq SL, Singh S, et al. Validation of the St. George's Respiratory Questionnaire in Nepal. Chronic Obstr Pulm Dis. 2015;2(4):281-289doi: 10.15326/jcopdf.2.4.2014.0156.
Sherpa, C. T., LeClerq, S. L., Singh, S., Naithani, N., Pangeni, R., Karki, A., Chokhani, R. K., Han, M., Gyetko, M., Tielsch, J. M., & Checkley, W. (2015). Validation of the St. George's Respiratory Questionnaire in Nepal. Chronic obstructive pulmonary diseases (Miami, Fla.), 2(4), 281-289. https://doi.org/10.15326/jcopdf.2.4.2014.0156
Sherpa, Chundak T, et al. "Validation of the St. George's Respiratory Questionnaire in Nepal." Chronic obstructive pulmonary diseases (Miami, Fla.) vol. 2,4 (2015): 281-289. doi: https://doi.org/10.15326/jcopdf.2.4.2014.0156
Sherpa CT, LeClerq SL, Singh S, Naithani N, Pangeni R, Karki A, Chokhani RK, Han M, Gyetko M, Tielsch JM, Checkley W. Validation of the St. George's Respiratory Questionnaire in Nepal. Chronic Obstr Pulm Dis. 2015 Sep 02;2(4):281-289. doi: 10.15326/jcopdf.2.4.2014.0156. PMID: 28848850; PMCID: PMC5556824.
Copy Download .nbib Format: NLM
Prevalence and Comorbidities of Chronic Obstructive Pulmonary Disease Among Adults in Kentucky Across Gender and Area Development Districts, 2011.

Chronic obstructive pulmonary diseases (Miami, Fla.)

Kamour A, David M, Kanotra S.
PMID: 28848852
Chronic Obstr Pulm Dis. 2015 Oct 15;2(4):296-312. doi: 10.15326/jcopdf.2.4.2015.0138.

No abstract available.

Cite
Kamour A, David M, Kanotra S. Prevalence and Comorbidities of Chronic Obstructive Pulmonary Disease Among Adults in Kentucky Across Gender and Area Development Districts, 2011. Chronic Obstr Pulm Dis. 2015;2(4):296-312doi: 10.15326/jcopdf.2.4.2015.0138.
Kamour, A., David, M., & Kanotra, S. (2015). Prevalence and Comorbidities of Chronic Obstructive Pulmonary Disease Among Adults in Kentucky Across Gender and Area Development Districts, 2011. Chronic obstructive pulmonary diseases (Miami, Fla.), 2(4), 296-312. https://doi.org/10.15326/jcopdf.2.4.2015.0138
Kamour, Abdulbaset, et al. "Prevalence and Comorbidities of Chronic Obstructive Pulmonary Disease Among Adults in Kentucky Across Gender and Area Development Districts, 2011." Chronic obstructive pulmonary diseases (Miami, Fla.) vol. 2,4 (2015): 296-312. doi: https://doi.org/10.15326/jcopdf.2.4.2015.0138
Kamour A, David M, Kanotra S. Prevalence and Comorbidities of Chronic Obstructive Pulmonary Disease Among Adults in Kentucky Across Gender and Area Development Districts, 2011. Chronic Obstr Pulm Dis. 2015 Oct 15;2(4):296-312. doi: 10.15326/jcopdf.2.4.2015.0138. PMID: 28848852; PMCID: PMC5556826.
Copy Download .nbib Format: NLM
The Human Microbiome in the Lung: Are Infections Contributing to Lung Health and Disease?.

Chronic obstructive pulmonary diseases (Miami, Fla.)

Gates K, Martinez F.
PMID: 28848868
Chronic Obstr Pulm Dis. 2016 Jan 15;3(1):466-472. doi: 10.15326/jcopdf.3.1.2015.0174.

This article serves as a CME-available, enduring material summary of the following COPD9

Cite
Gates K, Martinez F. The Human Microbiome in the Lung: Are Infections Contributing to Lung Health and Disease?. Chronic Obstr Pulm Dis. 2016;3(1):466-472doi: 10.15326/jcopdf.3.1.2015.0174.
Gates, K., & Martinez, F. (2016). The Human Microbiome in the Lung: Are Infections Contributing to Lung Health and Disease?. Chronic obstructive pulmonary diseases (Miami, Fla.), 3(1), 466-472. https://doi.org/10.15326/jcopdf.3.1.2015.0174
Gates, Khalilah, and Martinez, Fernando. "The Human Microbiome in the Lung: Are Infections Contributing to Lung Health and Disease?." Chronic obstructive pulmonary diseases (Miami, Fla.) vol. 3,1 (2016): 466-472. doi: https://doi.org/10.15326/jcopdf.3.1.2015.0174
Gates K, Martinez F. The Human Microbiome in the Lung: Are Infections Contributing to Lung Health and Disease?. Chronic Obstr Pulm Dis. 2016 Jan 15;3(1):466-472. doi: 10.15326/jcopdf.3.1.2015.0174. PMID: 28848868; PMCID: PMC5559128.
Copy Download .nbib Format: NLM
Back to the Future: Past, Present, and Future is COPD360.

Chronic obstructive pulmonary diseases (Miami, Fla.)

Hess MW, Make B.
PMID: 28848869
Chronic Obstr Pulm Dis. 2016 Jan 15;3(1):473-478. doi: 10.15326/jcopdf.3.1.2015.0173.

The treatment and management of chronic obstructive pulmonary disease (COPD) have gone through significant changes over the past decade. This plenary session, part of the 2015 COPD9USA conference, examines how the diagnosis and management of COPD has become more...

Cite
Hess MW, Make B. Back to the Future: Past, Present, and Future is COPD360. Chronic Obstr Pulm Dis. 2016;3(1):473-478doi: 10.15326/jcopdf.3.1.2015.0173.
Hess, M. W., & Make, B. (2016). Back to the Future: Past, Present, and Future is COPD360. Chronic obstructive pulmonary diseases (Miami, Fla.), 3(1), 473-478. https://doi.org/10.15326/jcopdf.3.1.2015.0173
Hess, Michael W, and Make, Barry. "Back to the Future: Past, Present, and Future is COPD360." Chronic obstructive pulmonary diseases (Miami, Fla.) vol. 3,1 (2016): 473-478. doi: https://doi.org/10.15326/jcopdf.3.1.2015.0173
Hess MW, Make B. Back to the Future: Past, Present, and Future is COPD360. Chronic Obstr Pulm Dis. 2016 Jan 15;3(1):473-478. doi: 10.15326/jcopdf.3.1.2015.0173. PMID: 28848869; PMCID: PMC5559129.
Copy Download .nbib Format: NLM
Developing and Implementing Biomarkers and Novel Imaging in COPD.

Chronic obstructive pulmonary diseases (Miami, Fla.)

Bhatt SP, Han MK.
PMID: 28848871
Chronic Obstr Pulm Dis. 2016 Jan 15;3(1):485-490. doi: 10.15326/jcopdf.3.1.2015.0170.

This article serves as a CME available, enduring material summary of the following COPD9

Cite
Bhatt SP, Han MK. Developing and Implementing Biomarkers and Novel Imaging in COPD. Chronic Obstr Pulm Dis. 2016;3(1):485-490doi: 10.15326/jcopdf.3.1.2015.0170.
Bhatt, S. P., & Han, M. K. (2016). Developing and Implementing Biomarkers and Novel Imaging in COPD. Chronic obstructive pulmonary diseases (Miami, Fla.), 3(1), 485-490. https://doi.org/10.15326/jcopdf.3.1.2015.0170
Bhatt, Surya P, and Han, Meilan K. "Developing and Implementing Biomarkers and Novel Imaging in COPD." Chronic obstructive pulmonary diseases (Miami, Fla.) vol. 3,1 (2016): 485-490. doi: https://doi.org/10.15326/jcopdf.3.1.2015.0170
Bhatt SP, Han MK. Developing and Implementing Biomarkers and Novel Imaging in COPD. Chronic Obstr Pulm Dis. 2016 Jan 15;3(1):485-490. doi: 10.15326/jcopdf.3.1.2015.0170. PMID: 28848871; PMCID: PMC5559131.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 373 entries